Acetic Acid

Acetic Acid

SCHEMBL1592789

CC(=O)O.CC(C)(O)c1ccccc1CC[C@@H](SCC1CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[NaH]

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 known ✓ P03372 1/20 0.73
▸ ADRB2 known ✓ P07550 1/20 0.73
▸ ADRA2A known ✓ P08913 1/20 0.73
▸ ADRA2B known ✓ P18089 1/20 0.73
▸ ADRA2C known ✓ P18825 1/20 0.73
▸ CYSLTR1 Q9Y271 3/20 0.73
▸ CYP2C8 P10632 2/20 0.73
▸ CYSLTR2 Q9NS75 2/20 0.73
▸ MEN1 O00255 1/20 0.73
▸ RECQL P46063 1/20 0.73
▸ BLM P54132 1/20 0.73
▸ KMT2A Q03164 1/20 0.73
▸ ABCB11 O95342 1/20 0.73
▸ EGFR P00533 1/20 0.73
▸ NR3C1 P04150 1/20 0.73
▸ FYN P06241 1/20 0.73
▸ PGR P06401 1/20 0.73
▸ ADRB1 P08588 1/20 0.73
▸ ADORA3 P0DMS8 1/20 0.73
▸ CHRM1 P11229 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL1133382 1.00 CYSLTR1 (0.73) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL4540935 0.99 CYSLTR1 (0.74) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL4540939 0.99 CYSLTR1 (0.74) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL1115925 0.99 CYSLTR1 (0.74) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL1768658 0.99 CYSLTR1 (0.74) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL1204496 0.99 CYSLTR1 (0.74) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL1204492 0.99 CYSLTR1 (0.74) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL6111295 0.99 CYSLTR1 (0.73) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL1592793 0.99 CYSLTR1 (0.73) CYSLTR1CYP2C8CYSLTR2MEN1RECQL
Acetic Acid SCHEMBL6111115 0.99 CYSLTR1 (0.73) CYSLTR1CYP2C8CYSLTR2MEN1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185517-B1 PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST AND AN INTERMEDIATE THEREOF MOEHS IBERICA SL (ES) 2012-09-19 — — EP disclosed
US-8163924-B2 Process for preparing a leukotriene antagonist and an intermediate thereof Moehs Ibérica, S.L. (ES) 2012-04-24 — — US disclosed
US-20110092708-A1 PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS THEREOF MYLAN LABORATORIES LIMITED (IN) 2011-04-21 — — US disclosed
US-7858793-B2 Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates SATYANARAYANA CHAVA 2010-12-28 — — US disclosed
US-20100204476-A1 Process for preparing a leukotriene antagonist and an intermediate thereof MOEHS IBERICA S.L. (ES) 2010-08-12 — — US disclosed
EP-2185517-A1 PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST AND AN INTERMEDIATE THEREOF Moehs Ibérica, S.L. (ES) 2010-05-19 — — EP disclosed
WO-2009016191-A1 PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST AND AN INTERMEDIATE THEREOF Moehs Ibérica, S.L. (ES) 2009-02-05 — — WO disclosed
US-20080275243-A1 Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts SATYANARAYANA CHAVA 2008-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092708-A1 PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS THEREOF CMA1, LTC4S, LTA4H ESR1 4609/4885ADRB2 200/4885ADRA2A 295/4885
US-20080275243-A1 Process for the Preparation of Polymorphs, Solvates of Aripiprazole Using Aripiprazole Acid Salts HTR3C, HTR3B, TPMT ESR1 2382/4885ADRB2 452/4885ADRA2A 575/4885
US-20100204476-A1 Process for preparing a leukotriene antagonist and an intermediate thereof CYSLTR2, LTB4R2, LTA4H ESR1 4537/4885ADRB2 999/4885ADRA2A 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback